期刊文献+

^(99)锝-亚甲基二膦酸盐联合甲泼尼龙治疗甲状腺相关眼病疗效分析 被引量:5

^(99)Tc-MDP combined with methylprednisolone sodium succinate in treatment of thyroid-associated ophthalmopathy: an analysis of clinical efficacy
原文传递
导出
摘要 目的观察99锝-亚甲基二膦酸盐注射液(99 Tc-MDP,商品名:云克)联合甲泼尼龙琥珀酸钠粉针治疗甲状腺相关眼病(TAO)的疗效。方法将病程都在1年以内的42例TAO患者随机分为2组:实验组应用99 Tc-MDP联合甲泼尼龙琥珀酸钠粉针冲击治疗,口服泼尼松片40mg/d,1个月后停药;对照组应用甲泼尼龙琥珀酸钠粉针冲击治疗,口服泼尼松片40mg/d,4个月后停药。评价治疗前后两组患者的突眼度及TAO眼病活动性,并进行组间比较。结果两组TAO的临床症状均有改善,其中在突眼度方面,实验组有效率为90.9%(20/22),对照组有效率为65%(13/20),两组差异有统计学意义(P<0.05)。而两组TAO眼病活动性治疗效果比较,差异无统计学意义(P>0.05)。实验组未出现与99 Tc-MDP有关的不良反应。结论 99 Tc-MDP联合甲泼尼龙治疗甲状腺相关眼病在突眼度的改善方面具有较好的疗效,无明显不良反应,同时缩短了糖皮质激素的使用疗程。 Objective To observe the efficacy of technetium-99 methylenediphosphonate (99 Tc-MDP) combined with methylprednisolone sodium succinate (MSS) on thyroid-associated ophthalmopathy (TAO). Methods Totally 42 TAO patients with a disease course less than 1 years were randomly divided into two groups; the experimental group was treated with 99Tc MDP combined with MSS (40 mg/d for one month) and the control group was treated with MSS alone (40 mg/d for four months). The degree of exophthalmos and TAO activity were observed before and after treatment and were compared between the two groups. Results The clinical symptoms of TAO were improved in both groups. The effective rate for exophthalmos degree was 90. 9% (20/22) in the experimental group and 65 % (13/20) in the control group, and there was significant difference between the two groups ( P〈0.05 ). The clinical efficacies for TAO ophthahnopathy activity were not significantly different between the two groups (P〉0.05). No 99 Wc- MDP-associated adverse reactions were found in the experimental group. Conclusion 99 Tc-MDP combined with MSS shows satisfactory effect for treatment of thyroid-associated ophthalmopathy, especially for exophthalmia, with no 99 Tc-MDP-associated adverse reactions, and can shorten the period of corticosteroid treatment.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2012年第7期808-809,共2页 Academic Journal of Second Military Medical University
关键词 99锝-亚甲基二膦酸盐 甲泼尼龙 GRAVES眼病 technetium-99 methylenediphosphonate methylprednisolone Graves ophthalmopathy
  • 相关文献

参考文献7

二级参考文献14

  • 1桑士标,李清茹,吴翼伟,苏成海,张玮,董慎安.云克治疗甲亢伴浸润性突眼的疗效分析[J].苏州大学学报(医学版),2005,25(6):1106-1107. 被引量:17
  • 2李茂良 李明起 张毅 等.云克系列药品的特点和治疗原理.中华风湿病学杂志,2003,7:48-51.
  • 3卢倜章.^131I治疗Graves病概述.//潘中允.放射性核素治疗学.北京:人民卫生出版社,2006:75.
  • 4Heufelder AE. Pathogenesis of ophthalmopathy in autoimmune thyroid disease. Rev Endocr Mebtab Disord, 2000,1(1-2):87-95.
  • 5Acuna OM, Athannassaki I, Paysse EA. Association between thy roid-stimulating immunoglobulin levels and ocular findings in pedi atric patients with Graves disease. Trans Am Ophthalmol Soc 2007,105 : 146-150.
  • 6Wartofsky L. Radioiodine therapy for Graves disease: case selection and restrictions recommended to patients in North America. Thyroid, 1997,7(2) : 213-216.
  • 7Tominaga T, Yokoyama N, Nagataki S, et al. International differences in approaches to ^131I therapy for Graves disease: case selection and restrictions recommended to patients in Japan, Korea, and China. Thyroid, 1997,7(2) :217-220.
  • 8李茂良."云克"系列药物的特点和治疗机理研讨[C].全国核素治疗研讨论文集,1999.16~30
  • 9刘亚丽,陈宝娥,刘金龙.甲状腺功能亢进患者医嘱依从性对基础代谢率的影响[J].护理学杂志,2008,23(18):30-31. 被引量:4
  • 10韦智晓,李俊红,覃伟武,李亚范.云克配合^(131)I治疗Graves病合并Graves眼病的近期疗效[J].中国医学影像技术,2008,24(10):1644-1646. 被引量:12

共引文献22

同被引文献43

引证文献5

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部